Equinix Inc vs Inovio Pharmaceuticals Inc — how do they compare? Equinix Inc trades at $1,066.72 (market cap $101.87B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Equinix Inc is far larger — about 1296.9× Inovio Pharmaceuticals Inc's market cap, and Equinix Inc pays a 2% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| EQIX | INO | |
|---|---|---|
Market Cap | $101.87B | $78.55M |
Sector | Real Estate | Health |
52-Week High | $1.12K | $2.87 |
52-Week Low | $726.09 | $0.66 |
Enterprise Value | $123.00B | $49.56M |
Dividend Yield | 2% | — |
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,049.99, up 0.63% today, with a neutral technical signal as it hovers near resistance at $1,050. The stock shows strong analyst support (74.51% buy ratings) and a consensus price target of $1,120, driven by robust revenue growth, expanding net income margins to 15.63% in 2025, and positive news on AI infrastructure demand. However, high valuation ratios like a P/E of 66.44 and significant capital expenditures pose challenges.
The outlook remains positive due to sustained digital infrastructure demand and raised long-term guidance, but risks include elevated debt levels and earnings misses in recent quarters. Investors should weigh growth prospects against premium valuations and cash flow pressures from heavy investments.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Trailing returns across standard periods
Latest headlines on both assets
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →